公开(公告)号：US12102628B2

公开(公告)日：2024-10-01

申请号：US17706225

申请日：2022-03-28

申请人： Seinda Pharmaceutical Guangzhou Corporation

发明人： Hui Ouyang ,  Yong Qiu

IPC分类号： A61P27/02 ,  A61K9/00 ,  A61K31/06 ,  A61K31/216 ,  A61K31/222 ,  A61K31/24 ,  A61K31/4168 ,  A61K31/417 ,  A61K31/439 ,  A61K31/4406 ,  A61K31/46 ,  A61K31/498 ,  A61K31/551 ,  A61K31/5513 ,  A61P27/10 ,  C07C217/20 ,  C07C219/10 ,  C07D213/04 ,  C07D235/02 ,  C07D403/04 ,  C07D403/12 ,  C07D471/08 ,  C07D487/04 ,  C07D491/18

CPC分类号： A61K31/46 ,  A61K9/0048 ,  A61K31/24 ,  A61K31/4168 ,  A61K31/417 ,  A61K31/498 ,  A61K31/551 ,  A61P27/10

摘要： Compositions and methods useful in slowing, inhibiting, or regressing the progression of myopia, while minimizing pupil dilation and light sensitivity are provided herein. Provided compositions can include a muscarinic receptor antagonist and a miotic agent.

公开(公告)号：US20240307334A1

公开(公告)日：2024-09-19

申请号：US18407998

申请日：2024-01-09

申请人： Lieber Institute, Inc. ,  Oregon Health & Science University

发明人： Brady Maher ,  Joseph Bohlen ,  Thomas Scanlan

IPC分类号： A61K31/192 ,  A61K31/137 ,  A61K31/165 ,  A61K31/216 ,  A61K31/222 ,  A61K31/40 ,  A61K31/4025 ,  A61K31/439 ,  A61K31/445 ,  A61K31/4453 ,  A61K31/46 ,  A61K31/5386 ,  A61P25/28

CPC分类号： A61K31/192 ,  A61K31/137 ,  A61K31/165 ,  A61K31/216 ,  A61K31/222 ,  A61K31/40 ,  A61K31/4025 ,  A61K31/439 ,  A61K31/445 ,  A61K31/4453 ,  A61K31/46 ,  A61K31/5386 ,  A61P25/28

摘要： The use of sobetirome or a prodrug or derivative thereof, including Sob-AM2, for treating a disease, disorder, or condition associated with or suspected of being associated with dysmyelination, such as Pitt-Hopkins Syndrome, is disclosed.

公开(公告)号：US12070501B1

公开(公告)日：2024-08-27

申请号：US17976660

申请日：2022-10-28

申请人： ADS Therapeutics LLC

发明人： Jinsong Ni ,  Van Dinh ,  Rong Yang

IPC分类号： A01N43/00 ,  A01N43/46 ,  A61K9/00 ,  A61K31/46 ,  A61K31/55 ,  A61K47/06 ,  A61K47/14 ,  A61P27/10

CPC分类号： A61K47/14 ,  A61K9/0048 ,  A61K31/46 ,  A61K47/06 ,  A61P27/10

摘要： A topical ophthalmological composition includes a muscarinic receptor antagonist as an active pharmaceutical ingredient; and medium chain triglycerides (MCTs) or light liquid paraffin oil as liquid vehicle. The topical ophthalmological composition treats an ocular disease.

公开(公告)号：US20240269133A1

公开(公告)日：2024-08-15

申请号：US18561405

申请日：2022-05-20

申请人： Purdue Pharma L.P.

发明人： Garth WHITESIDE ,  Stephen HARRIS

IPC分类号： A61K31/498 ,  A61K31/137 ,  A61K31/216 ,  A61K31/4025 ,  A61K31/46 ,  A61K31/4725 ,  A61P13/10

CPC分类号： A61K31/498 ,  A61K31/137 ,  A61K31/216 ,  A61K31/4025 ,  A61K31/46 ,  A61K31/4725 ,  A61P13/10

摘要： The disclosure provides a method of treating interstitial cystitis/bladder pain syndrome in a human subject in need of such treatment, comprising administering to the human subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. In certain embodiments, the method comprises administering the compound of formula (IA).

公开(公告)号：US20240262832A1

公开(公告)日：2024-08-08

申请号：US18288928

申请日：2022-04-28

申请人： Vanqua Bio, Inc.

发明人： Kevin Hunt ,  Jianbin Zheng ,  Sida Shen

IPC分类号： C07D487/04 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/46 ,  A61K31/497 ,  A61K31/4985 ,  A61K31/501 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5377 ,  C07D211/52 ,  C07D401/04 ,  C07D401/06 ,  C07D401/14 ,  C07D405/06 ,  C07D405/14 ,  C07D413/06 ,  C07D413/12 ,  C07D413/14 ,  C07D417/06 ,  C07D417/14 ,  C07D471/04

CPC分类号： C07D487/04 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/46 ,  A61K31/497 ,  A61K31/4985 ,  A61K31/501 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5377 ,  C07D211/52 ,  C07D401/04 ,  C07D401/06 ,  C07D401/14 ,  C07D405/06 ,  C07D405/14 ,  C07D413/06 ,  C07D413/12 ,  C07D413/14 ,  C07D417/06 ,  C07D417/14 ,  C07D471/04

摘要： Provided herein are compounds that modulate glucocerebrosidase (GCase), an enzyme whose activity is associated with neurological diseases and disorders (e.g., Gaucher's disease. Parkinson's disease). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating GCase-related diseases and disorders (e.g., Gaucher's disease. Parkinson's disease) with the compounds in a subject, by administering the compounds and/or compositions described herein.

公开(公告)号：US20240226004A1

公开(公告)日：2024-07-11

申请号：US18606272

申请日：2024-03-15

申请人： KINDEVA DRUG DELIVERY L.P.

发明人： Philip A. JINKS

IPC分类号： A61K9/00 ,  A61K31/46 ,  A61K47/06

CPC分类号： A61K9/008 ,  A61K31/46 ,  A61K47/06

摘要： Stable composition of anhydrous micronized ipratropium or a pharmaceutically acceptable anhydrous salt thereof and method of making.

公开(公告)号：US20240207279A1

公开(公告)日：2024-06-27

申请号：US18420659

申请日：2024-01-23

申请人： Cardix Therapeutics LLC

发明人： Jin Jean Wang ,  Gerald J. Yakatan ,  Ting N. Lin ,  Jing H. Gao

IPC分类号： A61K31/522 ,  A61K31/137 ,  A61K31/4402 ,  A61K31/4422 ,  A61K31/455 ,  A61K31/46 ,  A61K31/575 ,  A61P9/06

CPC分类号： A61K31/522 ,  A61K31/137 ,  A61K31/4402 ,  A61K31/4422 ,  A61K31/455 ,  A61K31/46 ,  A61K31/575 ,  A61P9/06

摘要： Provided herein is a pharmaceutical composition comprising two or more compounds, wherein each compound is independently a phosphodiesterase inhibitor, an adenosine receptor antagonist, a calcium channel blocker, a histamine H1-receptor agonist, a histamine H2-receptor agonist, a histamine H3-receptor antagonist, or a β2-adrenoreceptor agonist. Also provided herein is a method of treating, preventing, or ameliorating a cardiovascular disease in a subject, comprising administering to the subject in need thereof two or more compounds, wherein each compound is independently a phosphodiesterase inhibitor, an adenosine receptor antagonist, a calcium channel blocker, a histamine H1-receptor agonist, a histamine H2-receptor agonist, a histamine H3-receptor antagonist, or a β2-adrenoreceptor agonist.

公开(公告)号：US20240165098A1

公开(公告)日：2024-05-23

申请号：US18539823

申请日：2023-12-14

申请人： Sydnexis, Inc.

发明人： Gregory I. OSTROW ,  Kenneth J. WIDDER ,  David S. BAKER

IPC分类号： A61K31/46 ,  A61K9/00 ,  A61K47/02

CPC分类号： A61K31/46 ,  A61K9/0048 ,  A61K47/02

摘要： Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.

公开(公告)号：US11957832B2

公开(公告)日：2024-04-16

申请号：US17062185

申请日：2020-10-02

申请人： Norton (Waterford) Limited

发明人： Declan Walsh ,  Paul Prendergast ,  Daniel Buck ,  Trevor Kent ,  Niall Thompson

IPC分类号： A61M15/00 ,  A61K31/46 ,  A61K31/575 ,  A61M16/00 ,  A61M16/20 ,  A61M39/24 ,  B29C45/37

CPC分类号： A61M15/0095 ,  A61K31/46 ,  A61K31/575 ,  A61M15/009 ,  A61M16/208 ,  A61M39/24 ,  A61M15/0026 ,  A61M15/0068 ,  A61M2016/0015 ,  A61M2039/242 ,  A61M2039/244 ,  A61M2202/064 ,  A61M2207/10 ,  B29C45/37 ,  B29K2995/0072 ,  B29K2995/0073

摘要： A breath actuated metered dose inhaler may comprise a canister fire system configured to fire a medicament containing canister in response to patient inhalation. The canister fire system may comprise a pneumatic force holding unit and having a rest configuration in which a metering valve of the canister is in a refill configuration; a prepared configuration in which a canister actuation force is retained by the pneumatic force holding unit and the canister fire system is actuatable by patient inhalation induced airflow; and a fire configuration in which the metering valve is in a dose delivery position. When in the prepared configuration, the force retained by the pneumatic force holding unit may be reduced by less than about 6% over a period of 5 minutes, preferably less than about 3% over a period of 5 minutes.

公开(公告)号：US20240115551A1

公开(公告)日：2024-04-11

申请号：US18529306

申请日：2023-12-05

申请人： Glaukos Corporation

发明人： Xiaojun Michael Liu ,  James Jane-Guo Shiah ,  Gabriella Szekely

IPC分类号： A61K31/4178 ,  A61K9/00 ,  A61K9/06 ,  A61K31/27 ,  A61K31/46 ,  A61K31/498 ,  A61K31/5575 ,  A61K31/56 ,  A61K38/13 ,  A61K47/02 ,  A61K47/12

CPC分类号： A61K31/4178 ,  A61K9/0048 ,  A61K9/06 ,  A61K31/27 ,  A61K31/46 ,  A61K31/498 ,  A61K31/5575 ,  A61K31/56 ,  A61K38/13 ,  A61K47/02 ,  A61K47/12

摘要： Described herein are formulations including pharmaceutical agents comprising ester and/or lactone ring structures, and methods of using the same. The invention is also directed to a method and ophthalmic pharmaceutical compositions including solution and semisolid dosage forms (i.e. ophthalmic creams, gels, lotions, serums, and/or ointments) of treating a patient with various ocular diseases including presbyopia and dry eyes. The method comprising instructing a patient to apply one strip of the ophthalmic composition to the eyelids that includes pilocarpine or other active pharmaceutical ingredients containing ester and/or lactone ring structures with and without the buffering system.